What question did this study set out to answer?

The research aims to evaluate the effectiveness of elisrasib in patients with KRAS G12C-mutant non-small cell lung cancer.

April 23, 2026

Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC

Key Points

The research aims to evaluate the effectiveness of elisrasib in patients with KRAS G12C-mutant non-small cell lung cancer.
Phase I/II clinical trial
Patients with locally advanced or metastatic KRAS G12C-mutant NSCLC treated with elisrasib
Assessment of clinical responses and disease control rates
98.5% disease control rate in KRAS G12C inhibitor-naïve patients
83.9% disease control rate in patients refractory to other KRAS inhibitors
Demonstrated robust and durable clinical responses

Abstract

In a phase I/II clinical trial, patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer treated with the next-generation KRASG12C inhibitor elisrasib showed robust and durable clinical responses. Patients naïve to KRASG12C inhibitors, as well as those refractory to other such drugs, experienced high rates of disease control-98.5% and 83.9%, respectively.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

A Tue, study studied this question.

synapsesocial.com/papers/69e9b95b85696592c86ec25b — DOI: https://doi.org/10.1158/2159-8290.cd-nw2026-0041

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider